Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Baglin, A."'
Autor:
Ty E. Adams, Stéphanie G. I. Polderdijk, Trevor Baglin, Rodney M. Camire, Lacramioara Ivanciu, James A. Huntington
Publikováno v:
Blood. 129:105-113
Hemophilia is a bleeding disorder caused by deficiency in factors VIII or IX, the two components of the intrinsic Xase complex. Treatment with replacement factor can lead to the development of inhibitory antibodies, requiring the use of bypassing age
Publikováno v:
Blood. 91:1140-1144
A new factor V mutation associated with resistance to activated protein C and thrombosis (factor V Cambridge, Arg306→Thr) was found in one patient from a carefully selected group of 17 patients with venous thrombosis and confirmed APC resistance in
Publikováno v:
Blood. 124(12)
In this study, we describe a novel thrombomodulin (TM) mutation (c.1611C>A) that codes for a change from cysteine 537 to a premature stop codon (p.Cys537Stop). Three members of a family with a history of posttraumatic bleeding were identified to be h
Publikováno v:
Blood. 96:1816-1819
Cytochrome P-450 2C9 is the principle enzyme that terminates the anticoagulant effect of warfarin. Genetic polymorphisms inCYP2C9 producing variants with altered catalytic properties have been identified. Patients (n = 561) with a target internationa
Publikováno v:
Blood. 91:508-515
The importance of lipoproteins in the etiology of atherosclerosis is well established. Evidence is now accumulating to implicate thrombin in the pathogenesis of atherosclerosis. We have investigated whether atherogenic lipoproteins can support thromb
Publikováno v:
Europe PubMed Central
Plasma and platelet factor Va represent different substrates for activated protein C (APC). In this study, we have measured platelet-dependent APC resistance and the effect of aspirin and a platelet glycoprotein IIbIIIa antagonist (GR144053F) on this
Autor:
Debourdeau Philippe, Nissim Haim, Shaker S Mousa, Michel Marthy, C. Baglin, Beckers Marielle, Konstantin Syrigos, Martin H. Prins, Harry R. Büller, Mohammed H. Qari, Mario Mandalà, Ajay K. Kakkar, Manuel Monreal, Paolo Prandoni, Benjamin Brenner, Grigoris T. Gerotziafas, Ingrid Pabinger, Farge Dominique, Simon Noble, Michael B. Streiff, Anna Falanga, Alok A. Khorana, Ramón Lecumberri, Henri Bounameaux, Dialina Brilhante, Rupert Bauersachs
Publikováno v:
Blood. 120:1161-1161
Abstract 1161 Background Heterogeneity in clinical practices worldwide for Venous Thromboembolism (VTE) is a major challengs. This concern led us to establish international good clinical practices guidelines (GCPG) for the management VTE in cancer pa
Publikováno v:
Blood. 108:4131-4131
Experiments in mice have suggested that TNFα can reduce thrombosis in vivo. Cambien et al., (2003) found that administration of TNFα decreased platelet aggregation, expression of P-selectin and binding of fibrinogen. This correlated with an increas
Autor:
Peter William Collins, S. A. Brown, Raina Liesner, Trevor Baglin, C. R. M. Hay, Michael Makris, Gerry Dolan, John Hanley, David Keeling
Publikováno v:
Blood. 106:322-322
The literature on acquired haemophilia A (AH) predominantly consists of tertiary referral centre patients. This may have introduced referral and reporting bias with younger and more severely affected patients over-represented. This study reports all
Publikováno v:
Blood. 104:1718-1718
Heparin cofactor II(HCII) is a serpin which specifically inhibits thrombin. Like antithrombin(AT) it requires glycosaminoglycan(GAG) binding before full activation. However unlike antithrombin no specific activators have been identified. What current